Shares of Baxter International Inc. (NYSE: BAX - Get Free Report) have been assigned a consensus rating of "Hold" from the thirteen analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to

Baxter International (NYSE: BAX - Get Free Report) and Zynex (NASDAQ: ZYXI - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends. Insider and Institutional Ownership 90.2% of Baxter International shares

BAX introduces the IV Verify system to improve IV labeling accuracy, targeting medication safety gaps and boosting workflow efficiency in clinical settings.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and platforms, today debuted the IV Verify Line Labeling System, an automated solution, at the 2026 American Organization for Nursing Leadership Conference. The IV Verify system is designed to streamline nursing workflows, save clinician time and support safer medication administration at the bedside. Baxter's launch of the product is the result of a strategic and exclusive distrib.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, May 5, 2026 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2026 Annual Meeting. Online access to the 2026 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2026 Annual Meeting in person. The virtual format provides a safe, c.

Largest Single Investment from a Corporate Foundation Aims to Strengthen Healthcare Resilience by Advancing Therapy Animal Visits in U.S. Healthcare Settings BELLEVUE, Wash. and DEERFIELD, Ill.

The European Union's medicines regulator said on Tuesday it expects Baxter International's cancer drugs containing ifosfamide will ​remain in shortage in the bloc well ‌into the first quarter of next year.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Joel Grade. Mr. Grade is leaving the company to prioritize family matters but will continue in an advisory capacity until April 30, 2026. Baxter has named Anita Zielinski as interim CFO, effective immediately, while the company conducts its search to fill the role. Ms. Zielinski joined Baxter in 2025 as senio.

Baxter International Inc. (BAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Baxter International faces deep investor skepticism after disappointing guidance and management's decision to delay its Investor Day. Recent leadership changes and a flattened organizational structure are part of a turnaround effort, which is off to an admittedly bumpy start. But valuation is reasonable enough that BAX is a straight bet on the turnaround working.